

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF CALIFORNIA

GARY WAYNE ERVIN,  
Plaintiff,  
v.  
JAMES DRENNAN, et al.,  
Defendants.

No. 2:19-cv-01883-KJM-CKD PS

FINDINGS AND RECOMMENDATIONS  
(ECF No. 52)

Presently before the court is defendants’ motion to dismiss plaintiff’s Second Amended Complaint (“SAC”).<sup>1</sup> (ECF No. 52.) The motion was taken under submission pursuant to Local Rule 230(g) (ECF No. 57), and the court has considered defendants’ memorandum in support of their motion, plaintiff’s opposition, and defendants’ reply. (ECF Nos. 52.1, 56, 58.) For the following reasons, the undersigned recommends GRANTING IN PART defendants’ motion and dismissing plaintiff’s claims against certain defendants with prejudice.

///  
///  
///  
///

---

<sup>1</sup> Plaintiff is proceeding pro se, and this action is before the undersigned pursuant to Eastern District of California Local Rule 302(c)(21).

1 **BACKGROUND**

2 **A. Factual Background**<sup>2</sup>

3 For at least the last 22 years, plaintiff has suffered from psoriasis, a condition that results  
4 in skin irritation, which plaintiff claims causes him extreme burning pain when not medically  
5 controlled. (ECF No. 49 at 3, 8-9.) In September 2009, after trying many treatments and  
6 medicines that failed to control his symptoms, plaintiff’s dermatologist at Kaiser Permanente  
7 prescribed him “the miracle medicine ENBREL”<sup>3</sup> for his psoriasis. (Id. at 3.) Plaintiff was  
8 started on two shots of Enbrel per week and later reduced to one shot per week, which he  
9 continued to self-administer until he was arrested in May 2018. (Id.)

10 This suit arises from plaintiff’s claim that he was unconstitutionally deprived of this  
11 Enbrel medication for approximately 12 weeks, from his arrest and detention through July 2018  
12 when he was restarted on Enbrel after filing a grievance. (Id. at 3-4, 27, 29.) The SAC asserts  
13 deliberate indifference claims for inadequate medical care, under 42 U.S.C. § 1983, against five  
14 physicians and a pharmacist who all work for the Sacramento County jails based on the following  
15 allegations. (Id. at 1-3.)

16 Plaintiff was arrested on May 8, 2018 and placed in pretrial detention at the Main Jail of  
17 Sacramento County. (Id. at 3.) During intake that day, a Sherriff’s medical reviewer took down  
18 plaintiff’s medical information, including his “‘specialty’ medicine,” Enbrel; but Sherriff’s  
19 personnel did not immediately obtain plaintiff’s medical records from Kaiser. (Id.) The next day,  
20 May 9, 2018, plaintiff had a walk-in appointment for “warfarin dosing” with defendant Dr. James  
21 Drennan who arranged for plaintiff to receive warfarin and another previously prescribed  
22 medication but “avoided getting [him] set up with Enbrel.” (Id. at 3, 12.) Dr. Drennan noted that  
23 plaintiff was taking Enbrel for psoriasis and had signed a release of his Kaiser medical and

24 \_\_\_\_\_  
25 <sup>2</sup> Unless otherwise indicated, these facts are drawn from the Second Amended Complaint and the  
26 documents attached thereto. (ECF No. 49.) As was true in resolving the prior motion to dismiss,  
27 the court disregards any additional allegations asserted only in plaintiff’s opposition. (See ECF  
28 No. 48 at 7 (citing Schneider v. California Dept. of Corr., 151 F.3d 1194, 1197 n.1 (9th Cir.  
1998).)

<sup>3</sup> Although plaintiff capitalizes this medication throughout his pleadings, the court refers to the  
medication as “Enbrel” for easier readability.

1 pharmacy records, but the Kaiser release was still “pending for meds.” (Id. at 3, 12 (Ex. 3).)  
2 Plaintiff alleges that Dr. Drennan “never made any arrangements for Plaintiff to get Enbrel” and  
3 “acted like he didn’t want to help Plaintiff with the matter.” This began a one-month period when  
4 plaintiff was “completely deprived of any psoriasis medicine.” (Id.)

5 On May 15, 2018, plaintiff had an appointment with defendant Dr. Janet Abshire who,  
6 post-examination, noted that plaintiff had missed one Enbrel shot, causing a psoriasis “flare” with  
7 “small coin lesions” appearing on at least his wrist and right leg, and that the Kaiser records were  
8 still pending. (Id. at 14 (Ex. 4).) Dr. Abshire “suggested Plaintiff could be given medical  
9 release” but “showed no interest in prescribing Enbrel.” (Id. at 4.) Plaintiff claims Dr. Abshire  
10 thereby “contributed to” the continuation of the one-month period in which plaintiff did not  
11 receive any psoriasis medication. (Id.)

12 Two days later, on May 17, 2018, plaintiff was transferred from the Main Jail to the Rio  
13 Cosumnes Correctional Center (“RCCC”), another county jail. (Id. at 4, 6, 15.) Plaintiff alleges  
14 that Drs. Abshire and Drennan “allowed [him] to be transferred” without getting his Enbrel  
15 medication. (Id. at 4.) Plaintiff further alleges that Dr. Abshire failed to place a “hold” to prevent  
16 his transfer despite suggesting that he might qualify for medical release. (Id.)

17 On May 24, 2018, plaintiff told a nurse that he needed to see a doctor to go over several  
18 medications he was not receiving. (Id. at 15 (Ex. 6).) Plaintiff alleges that this nurse “received a  
19 copy of Plaintiff’s Enbrel prescription (and Enbrel Specifications) dated April 25th, 2018, and  
20 stated the prescription into the Plaintiff’s medical record . . . .” (Id. at 4.) The nurse’s note  
21 entered in plaintiff’s medical record states in relevant part: “Pt has current RX Enbrel 50 mg/ml  
22 Pen 3.92mls sub Q, weekly that is current.states he is sta[r]ting to look like [a] cheetah.” (Id.  
23 at 15.) Plaintiff also attaches to the SAC a copy of his April 25, 2018 Enbrel prescription label.  
24 The prescription (from plaintiff’s Kaiser dermatologist) was for “ENBREL 50 MG/ML SURECK  
25 PEN-3.92MLS/BX,” specifying 50 mg injections subcutaneously once a week. (Id. at 10  
26 (Ex. 1).) According to plaintiff, the specifications dispensed with the medicine stated that

27 ///

28 ///

1 “Enbrel 50 mg/mL (0.98 mL) single dose prefilled SureClick autoinjector comes in a Carton of 4  
2 doses under AMGEN & Immunex Corporation No. NDC 58406-445-04.”<sup>4</sup> (Id. at 6.)

3 The next chronological medical record attached to the SAC is an entry dated May 27,  
4 2018 and electronically signed at 11:59 AM by defendant Dr. Grant Nugent, who was at the time  
5 the Medical Director of Sacramento County Jails Correctional Health Services. (Id. at 2, 20  
6 (Ex. 9A).) Dr. Nugent’s “General Note” on the subject of “Essential Meds” was entered without  
7 any personal examination of or communication with plaintiff, based purely on plaintiff’s medical  
8 file. (Id. at 6.) The entry reads, in relevant part:

9 [Plaintiff] states he was on Humira until he had to change to Enbrel  
10 because of insurance. He states that he is 3.92 mL of Enbrel—this  
11 would be 196 mg which is almost 4 times the FDA recommended  
12 dose for both plaque psoriasis and for psoriatic arthritis  
13 . . .  
14 Plan Humira 40 mg every two weeks

13 (Id. at 20 (capitalization altered to sentence case).) The note also prescribes two other  
14 medications and states “all meds and dosages [pending] receipt of information from Kaiser[.]”  
15 (Id.)

16 Plaintiff alleges that Dr. Nugent “fabricated” the first two above-quoted sentences of the  
17 entry (regarding plaintiff’s purported statements), committing “libel-per-se” by insinuating that  
18 that plaintiff “is a drug addict whose drug of choice is Enbrel and that [he] overdoses on 3.92  
19 milliliters” all at once. (Id. at 6.) Plaintiff claims that Dr. Nugent used this discrepancy as an  
20 excuse to terminate plaintiff’s 9-year prescription for Enbrel, and that he recklessly prescribed  
21 Humira instead, even though Humira has a “higher incidence of infections and malignancies” in  
22 patients over 65 years old (plaintiff is 77 years of age). (Id. at 7.) Plaintiff alleges that Dr.  
23 Nugent failed to use “common sense” by doubting the accuracy of plaintiff’s prescribed dosage.  
24 (Id.) He further alleges that Dr. Nugent “backdated” this entry from some later time in order to

---

25  
26 <sup>4</sup> A search of the FDA’s National Drug Code (“NDC”) Directory confirms that this NDC is  
27 assigned to Enbrel. Among the other publicly available product information listed therein is a  
28 description of the package as containing 4 syringes in 1 carton, with 1 mL per syringe. See  
National Drug Code Directory, <https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm> (last  
accessed 12/29/2020).

1 “cover[] up” the denial of Enbrel, which was intended to pressure plaintiff to post bail and leave  
2 the jail. (Id. at 5.) He asserts that defendant Drs. Drennan and Abshire were also involved in this  
3 “joint participation.” (Id.)

4 Related to these backdating and cover-up allegations, plaintiff describes a visit with  
5 another defendant, Dr. Robert Padilla, the next day, May 28, 2018. (Id. at 26.) During that visit,  
6 according to plaintiff, he and Dr. Padilla looked at the computerized medical record and found no  
7 entries by Dr. Nugent for the prior day. (Id. at 5.) Dr. Padilla’s medical notes for that visit reflect  
8 that plaintiff had a history of “Psoriatic arthritis treated with Enbrel 50 mg a week Rx from Kaiser  
9 hospital”; that plaintiff “state[d] he is doing well and has no complaints”; and that plaintiff was  
10 worried his Enbrel was not getting ordered in time. (Id. at 16 (Ex. 7).) The notes also reflect a  
11 plan to “continue Enbrel.” (Id.) Plaintiff returned to see Dr. Padilla two days later, on May 30,  
12 2018. (Id. at 5.) According to plaintiff, Dr. Padilla “was angered” by Dr. Nugent’s actions  
13 regarding Enbrel, and he and plaintiff discussed the possible need for plaintiff to file a grievance.  
14 (Id.)

15 The following week, on June 4, 2018, defendant Dr. Glayol Sahba entered a general note  
16 in plaintiff’s medical record indicating that staff was checking on whether plaintiff received a  
17 dose of his “biologic med,” presumably the Humira. (Id. at 26 (Ex. 14.)) Plaintiff alleges,  
18 without explanation, that Dr. Sahba had joined the “joint participation” to backdate Dr. Nugent’s  
19 medical records, and that this note shows there was “excitement and concern among some staff  
20 members to get the matter calmed down.” (Id. at 8.) He further alleges that Dr. Sahba “acted as a  
21 fixer for [Dr.] Nugent to get bad circumstances calmed down.” (Id.) And plaintiff also notes that  
22 although the “maintenance costs” of Enbrel and Humira are about the same, Dr. Sahba and the  
23 other “joint participants” never notified plaintiff so that he could “seek his rights earlier.” (Id.)

24 Plaintiff alleges that the last defendant, pharmacist Steve Carter, also was “in joint  
25 participation with [Dr.] Nugent and others in unlawful activities against [plaintiff’s] psoriasis  
26 health interests.” (Id. at 7.) Plaintiff points to a June 5, 2018 prescription for adalimumab (brand  
27 name Humira) set to start on June 15, 2018 and stop on September 13, 2018, which was entered  
28 in plaintiff’s medical record by defendant Carter. (Id. at 25 (Ex. 13).) Plaintiff asserts that this

1 prescription “was not lawfully signed for by a physician MD” and that Carter should have  
2 realized it unlawfully referred to Dr. Nugent’s backdated information. (Id. at 7.)

3 On June 13, 2018, plaintiff filed an internal administrative grievance complaining of not  
4 receiving Enbrel for his psoriatic arthritis, and instead receiving Humira medication that was not  
5 effective. (Id. at 5, 29 (Ex. 17) (grievance reply).) Dr. Nugent received “referral and control” of  
6 the grievance, which he “caused to be rejected.” (Id. at 5.)

7 On June 29, 2018, plaintiff returned to Dr. Padilla, who allegedly “encouraged [him] to  
8 get Enbrel by staying with [his] grievance.” (Id. at 5.) Plaintiff claims that “Dr. Padilla was  
9 aware of local grievance assignment practices and expected Plaintiff would fail in the grievance  
10 and abandon any thoughts of appealing the grievance.” (Id.) Plaintiff asserts that Dr. Padilla did  
11 not want to “stand at odds” with Dr. Nugent so did not report Dr. Nugent’s “obnoxious behavior”;  
12 instead, he helped Dr. Nugent “cover up his unconstitutional behavior.” (Id.)

13 On July 19, 2018, after plaintiff appealed his grievance, he was seen by a different doctor  
14 who restarted him on Enbrel. (Id. at 8.) The doctor’s notes from this encounter state, in part:

15 **Subjective:** Pt states that plaque psoriasis and psoriatic arthritis.  
16 [sic] Been on Enbrel (50/wk) for the past 5-6yrs on the outs. When  
17 came here was started on Humira once every 2wks. States this is not  
18 enough to control his [symptoms] and now is all flared up.

18 Noted that MD note from 5/27/18 states his prior request appeared to  
19 be “4 times the recommended dose”, that’s why was started on  
20 Humira instead, pending records from Kaiser (still do not have access  
21 to these).

20 (Id. at 27 (Ex. 15).) In the “Objective” portion of the note, the doctor observed on plaintiff’s legs  
21 scattered plaques, erythema (skin reddening), and at least one “reddened lesion with serious  
22 drainage.” (Id.) The doctor discontinued plaintiff’s Humira prescription, ordering him back onto  
23 Enbrel instead—twice a week for three months, and then weekly. The doctor also ordered  
24 doxycycline “for mild skin infections” and follow-up wound care to assist with debridement of  
25 one of the lesion plaques. (Id.)

26 Shortly thereafter, plaintiff received a reply to his grievance stating that his complaint had  
27 been addressed by the above change to his plan of care. The reply states in part:

28 ////

1 The documentation in your medical file indicates the physician  
2 discussed the current Humira order with you and the reason the  
3 Humira was ordered and your request for Enbrel as the Humira is not  
4 effective, does not control your symptoms.

5 . . .  
6 The documentation in your medical file indicates the physician  
7 ordered the medication Enbrel Injection for you per your request and  
8 noted records are still pending from Kaiser regarding Enbrel.

9 (Id. at 29 (Ex. 17).) On September 7, 2018, plaintiff was released from custody. (Id. at 3.)

10 Overall, plaintiff claims that being deprived of Enbrel “destabilized” his psoriasis, causing  
11 the skin on his legs to start “burning up” and triggering a new form of psoriasis on his right leg  
12 resulting in all-day pain. (Id. at 8-9.)

### 13 **B. Procedural History**

14 Plaintiff filed the present action in September 2019 and subsequently filed a first amended  
15 complaint in February 2020. (ECF Nos. 1, 15.) On July 29, 2020, the undersigned granted  
16 defendants’ motion to dismiss, finding that the first amended complaint failed to state a claim for  
17 deliberate indifference against the same five doctors named in the current SAC. (ECF No. 48.)  
18 The court granted leave to amend, and on August 20, 2020, plaintiff filed the SAC. (ECF  
19 No. 49.) On September 8, 2020, defendants filed the instant motion to dismiss under  
20 Rule 12(b)(6), again for failure to state a claim. (ECF No. 52.)

### 21 **LEGAL STANDARD**

22 In considering a motion to dismiss for failure to state a claim upon which relief can be  
23 granted, the court must accept as true the allegations of the complaint in question, Erickson v.  
24 Pardus, 127 S. Ct. 2197, 2200 (2007), and construe the pleading in the light most favorable to the  
25 plaintiff, see Scheuer v. Rhodes, 416 U.S. 232, 236 (1974).

26 In order to avoid dismissal for failure to state a claim a complaint must contain more than  
27 “naked assertions,” “labels and conclusions” or “a formulaic recitation of the elements of a cause  
28 of action.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555-557 (2007). In other words,  
“[t]hreadbare recitals of the elements of a cause of action, supported by mere conclusory  
statements do not suffice.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). Furthermore, a claim  
upon which the court can grant relief has facial plausibility. Twombly, 550 U.S. at 570. “A

1 claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw  
2 the reasonable inference that the defendant is liable for the misconduct alleged.” Iqbal, 556 U.S.  
3 at 678.

#### 4 **DISCUSSION**

5 The SAC asserts a single cause of action against all six defendants: a § 1983 claim for  
6 deliberate indifference to plaintiff’s medical needs, in violation of the Fourteenth Amendment.  
7 (ECF No. 49 at 3.)

##### 8 **A. Motion to Dismiss**

9 In assessing the sufficiency of the SAC, the court applies the same standards described in  
10 the previous order granting dismissal with leave to amend, repeated here with some additional  
11 clarification in response to plaintiff’s opposition arguments. Deliberate indifference to a serious  
12 medical need violates the Eighth Amendment’s prohibition against cruel and unusual punishment.  
13 See Estelle v. Gamble, 429 U.S. 97, 104 (1976); McGuckin v. Smith, 974 F.2d 1050, 1059 (9th  
14 Cir. 1992), overruled on other grounds by WMX Techs, Inc. v. Miller, 104 F.3d 1133, 1136 (9th  
15 Cir. 1997) (en banc). In the context of pretrial detainees, as here, an inmate’s rights derive from  
16 the Fourteenth Amendment’s Due Process Clause rather than the Eighth Amendment’s Cruel and  
17 Unusual Punishments Clause. See Gibson v. County of Washoe, 290 F.3d 1175, 1187 (9th Cir.  
18 2002) (citing Bell v. Wolfish, 441 U.S. 520, 535 (1979)). Under the Fourteenth Amendment, a  
19 plaintiff’s claim is evaluated under an objective deliberate indifference standard.

20 [T]he elements of a pretrial detainee’s medical care claim against an  
21 individual defendant under the due process clause of the Fourteenth  
22 Amendment are: (i) the defendant made an intentional decision with  
23 respect to the conditions under which the plaintiff was confined; (ii)  
24 those conditions put the plaintiff at substantial risk of suffering  
25 serious harm; (iii) the defendant did not take reasonable available  
measures to abate that risk, even though a reasonable official in the  
circumstances would have appreciated the high degree of risk  
involved—making the consequences of the defendant’s conduct  
obvious; and (iv) by not taking such measures, the defendant caused  
the plaintiff’s injuries.

26 Gordon v. Cty. of Orange, 888 F.3d 1118, 1125 (9th Cir. 2018) (internal quotations omitted).

27 Regarding the third element of the Gordon test, the “defendant’s conduct must be  
28 objectively unreasonable, a test that will necessarily turn on the facts and circumstances of each



1 particular case.” Id. This differs from the Eighth Amendment test for deliberate indifference to  
2 the medical needs of convicted inmates which requires that the “prison official must subjectively  
3 have a sufficiently culpable state of mind.” Id. at 1125 n.4 (internal quotations omitted). Pretrial  
4 detainees like plaintiff need not prove the subjective elements of the Eighth Amendment  
5 deliberate indifference test, namely actually knowing of and consciously disregarding an  
6 excessive risk to inmate health or safety. Id. Still, plaintiff must allege more than objectively  
7 negligent conduct to bring a constitutional claim. See id. at 1125 (requiring pretrial detainee  
8 plaintiffs to “prove more than negligence but less than subjective intent—something akin to  
9 reckless disregard”). But again, to satisfy this quasi-reckless mental state element, pretrial  
10 detainees need only include allegations sufficient for the court to conclude that under an objective  
11 standard, a reasonable person in the official’s position would have realized the high degree of  
12 risk—not that the official in question actually realized such risk. Gordon, 888 F.3d at 1125; see  
13 Castro v. Cty. of Los Angeles, 833 F.3d 1060, 1071 (9th Cir. 2016) (en banc) (quoting  
14 Restatement (Second) of Torts § 500 cmt. a (Am. Law Inst. 2016) commentary on showing  
15 “reckless disregard” under objective standard).

16 Without a requirement to plead or prove a knowing or intentional disregard of whatever  
17 risks plaintiffs face in a given case, the Fourteenth Amendment deliberate indifference test is  
18 indeed “less stringent” than its Eighth Amendment corollary. Deloney v. Cty. of Fresno,  
19 No. 1:17-CV-01336-LJO-EPG, 2019 WL 1875588, at \*5 n.11 (E.D. Cal. Apr. 26, 2019).<sup>5</sup> But  
20 apart from the removal of this subjective element, the two tests otherwise continue to align. Thus,  
21 plaintiff is wrong to argue that numerous foundational Eighth Amendment cases have been  
22 “overruled” in the wake of this shift. (ECF No. 56 at 5-6.)

23 ///

---

24  
25 <sup>5</sup> In his opposition, plaintiff requests that the court take judicial notice of Chief Judge O’Neill’s  
26 opinion in Deloney, which plaintiff argues established precedent that is “binding on all judges” in  
27 this district. (ECF No. 56 at 1-2, 16.) Plaintiff’s position is incorrect. Only published opinions  
28 of the Ninth Circuit Court of Appeals (and the U.S. Supreme Court) bind this court. The Deloney  
opinion, although well-reasoned, is not binding authority. Nevertheless, the court has considered  
Deloney as persuasive authority alongside other non-binding opinions of sister district courts, and  
need not formally judicially notice the case to do so.

1 As before, “[i]ndifference may appear when prison officials deny, delay or intentionally  
2 interfere with medical treatment, or it may be shown by the way in which prison physicians  
3 provide medical care.” Jett v. Penner, 439 F.3d 1091, 1096 (9th Cir. 2006) (internal quotation  
4 marks omitted). And alleging that there was disagreement—either from the plaintiff, or another  
5 medical provider—as to what medications to prescribe also remains insufficient, by itself, to  
6 establish deliberate indifference. See Toguchi v. Chung, 391 F.3d 1051, 1058 (9th Cir. 2004)  
7 (mere difference of medical opinion is insufficient, as a matter of law, to establish deliberate  
8 indifference); Jackson v. McIntosh, 90 F.3d 330, 332 (9th Cir. 1996) (same). That said, after  
9 Gordon, for a pretrial detainee to state a claim based on “choices between alternative courses of  
10 treatment,” he must only allege that the chosen course of treatment “was medically unacceptable  
11 under the circumstances,” Toguchi, 391 F.3d at 1058—not that the chosen treatment was also  
12 chosen “in conscious disregard of an excessive risk to the prisoner’s health,” id. See Flentoil v.  
13 Santa Clara Cty. Dep’t of Corr., No. 18-CV-03486-EMC, 2020 WL 571025, at \*9 & n.6 (N.D.  
14 Cal. Feb. 5, 2020) (“‘Conscious disregard’ simply is not a part of the Fourteenth Amendment’s  
15 objective deliberate indifference test.”).

16 *1. Drs. Drennan & Abshire*

17 The court previously dismissed the claims against Drs. Drennan and Abshire because the  
18 first amended complaint contained only a threadbare recital of their involvement. (ECF No. 48  
19 at 5.) The SAC provides much more detail with respect to each, but the details now alleged only  
20 add up to a Fourteenth Amendment claim of deliberate indifference against Dr. Abshire.

21 Plaintiff’s claims against Dr. Drennan arise almost entirely from his failure to prescribe  
22 Enbrel to plaintiff at a walk-in appointment for a separate medication on his second day in  
23 custody. (See ECF No. 49 at 3, 12.) Based on plaintiff’s allegation that Dr. Drennan “avoided”  
24 setting him up with Enbrel, the SAC adequately pleads the first Gordon element of an “intentional  
25 decision” with respect to plaintiff’s conditions of confinement, Gordon, 888 F.3d at 1125, even if  
26 just barely. And Dr. Drennan does not dispute the second element regarding plaintiff’s risk of  
27 suffering serious harm. At the third element, however, the allegations fail.

28 ///

1           As plaintiff is well aware, for this element, he must allege facts from which the court can  
2 plausibly infer that Dr. Drennan “did not take reasonable available measures to abate [the] risk,  
3 even though a reasonable official in the circumstances would have appreciated the high degree of  
4 risk involved—making the consequences of the defendant’s conduct obvious.” Id. The SAC and  
5 the medical records incorporated by reference do not permit such an inference. Applying the  
6 objective standard, a reasonable doctor in Dr. Drennan’s circumstances—presented with an  
7 inmate patient whose medical release and records of existing prescriptions have only just been  
8 requested and remain pending from a pre-existing provider—would not necessarily appreciate  
9 any high degree of risk from waiting longer than one day to prescribe medication to prevent skin  
10 irritation.<sup>6</sup>

11           The same cannot be said for plaintiff’s claim against Dr. Abshire, however. By the time  
12 plaintiff was examined by Dr. Abshire on May 15, 2018, the Kaiser records request had been  
13 pending for one week, and plaintiff was presenting with symptoms that Dr. Abshire recognized as  
14 a psoriasis flare-up due to a missed dose of medication. (ECF No. 49 at 4, 14.) Taking plaintiff’s  
15 allegations as true, his symptoms were significant enough for Dr. Abshire to suggest medical  
16 release, but she did not order any sort of change to his treatment plan. The court liberally  
17 construes the SAC as alleging that Dr. Abshire made the “intentional decision” not to treat  
18 plaintiff’s psoriasis symptoms at all, in satisfaction of the first Gordon element; and the court  
19 finds these allegations sufficiently plead that a reasonable physician in such circumstances would  
20 have appreciated the high degree of risk from not treating plaintiff’s condition, satisfying the third  
21 Gordon element. Again, defendants do not dispute the seriousness of the risk that non-treatment  
22 created for plaintiff. As to the fourth Gordon element of causation, the court accepts as sufficient  
23 for purposes of this initial pleadings stage that Dr. Abshire’s failure to prescribe any medication  
24

---

25  
26 <sup>6</sup> The only additional allegations against Dr. Drennan are that he “allowed” plaintiff to be  
27 transferred to RCCC without an Enbrel prescription and was somehow involved in Dr. Nugent’s  
28 purported cover-up scheme. These allegations remain far too vague and speculative to state a  
claim of deliberate indifference.

1 to control plaintiff's psoriasis caused at least the pain and flare-ups plaintiff experienced during  
2 the following two weeks before he started receiving the Humira prescription after his transfer.

3 Accordingly, the court denies Dr. Abshire's motion to dismiss the SAC's claim that she  
4 was deliberately indifferent to plaintiff's medical needs by failing to provide treatment for  
5 plaintiff's psoriasis.<sup>7</sup> The allegations related to Dr. Abshire's failure to place a "hold" to prevent  
6 plaintiff's transfer and her participation in any subsequent cover-up efforts, however, are too  
7 vague and conclusory to state a separate claim under the Fourteenth Amendment. The motion  
8 should be granted as to any claims against Dr. Abshire arising from those allegations. Likewise,  
9 all claims against Dr. Drennan should be dismissed in their entirety.

10 2. Dr. Sahba & Mr. Carter

11 Plaintiff's claim against Dr. Sahba in the FAC was also dismissed for lack of detail, with  
12 leave to amend. (ECF No. 48 at 5.) The SAC now somewhat clarifies Dr. Sahba's challenged  
13 conduct but fails to adequately plead a deliberate indifference claim against Dr. Sahba. The SAC  
14 adds pharmacist Carter as a defendant for the first time and likewise fails to state a claim against  
15 him.

16 The SAC's claims against Dr. Sahba and Carter fail at the first element of the Gordon test.  
17 Apparently, Dr. Sahba's only involvement with plaintiff during his incarceration was to enter a  
18 note in plaintiff's medical record on June 4, 2018, indicating some confusion over whether  
19 plaintiff had received the "biologic med" he had been prescribed. (ECF No. 49 at 26.) The court  
20 cannot glean from the pleadings any point at which Dr. Sahba made an intentional decision  
21 regarding plaintiff's conditions of confinement. See Gordon, 888 F.3d at 1125. Plaintiff's other  
22 generalized accusations that Dr. Sahba acted as a "fixer" for Dr. Nugent and joined in the "joint  
23 participation" to pressure plaintiff to post bail are utterly unsupported by any specific factual  
24 allegations. See Twombly, 550 U.S. at 555 ("Factual allegations must be enough to rise above  
25

26  
27  
28 

---

<sup>7</sup> In so concluding, the court takes no position on plaintiff's ultimate ability to prove this claim; it merely concludes that the allegations are sufficient to survive the motion to dismiss.

1 the speculative level.”); Iqbal, 556 U.S. at 678 (complaint must contain sufficient factual matter  
2 to “state a claim to relief that is plausible on its face”).

3 Plaintiff’s allegations against defendant Carter are even more threadbare. Again, the court  
4 cannot identify within the pharmacist’s June 5, 2018 prescription entry any intentional decision  
5 regarding plaintiff’s conditions of confinement—regardless whether the prescription was properly  
6 authorized. There is no suggestion that Carter had any control over what medications plaintiff  
7 was or was not prescribed during his detention, or that he departed from a doctor’s prescription.  
8 See Curry v. California Forensic Med. Grp., No. 2:18-CV-2513 KJN P, 2020 WL 4501799, at \*9  
9 (E.D. Cal. Aug. 5, 2020) (granting summary judgment for administrator who undisputedly “was  
10 not responsible for prescribing medication to plaintiff and did not interfere with any medication  
11 prescription,” for failure to satisfy Gordon elements 1, 2, or 4). And plaintiff’s sweeping  
12 allegation that Carter participated in “unlawful activities against [plaintiff’s] psoriasis health  
13 interests” (ECF No. 49 at 7) does nothing to clarify how Carter was involved in the alleged  
14 deprivation. The claims against both Dr. Sahba and Mr. Carter are thus subject to dismissal.

15 3. Dr. Padilla

16 The court previously dismissed the FAC against Dr. Padilla for failure to allege any  
17 intentional decision regarding plaintiff’s medical treatment, or any objectively unreasonable  
18 conduct. (ECF No. 48 at 5.) In the SAC plaintiff largely repeats the same allegations asserted  
19 against Dr. Padilla in the FAC, continuing to portray Dr. Padilla as someone sympathetic to  
20 plaintiff’s medical complaints who tried to provide plaintiff with the medication he sought.  
21 The only substantive additions are plaintiff’s allegation that Dr. Padilla expected plaintiff to fail  
22 with his grievance pursuit and would not challenge Dr. Nugent’s prescription decision. (ECF  
23 No. 49 at 5.) These flimsy and speculative assertions are not enough to state a cognizable claim.  
24 Because plaintiff’s renewed claim against Dr. Padilla is substantially similar to the one dismissed  
25 in the FAC, the SAC’s claim against Dr. Padilla should also be dismissed.

26 4. Dr. Nugent

27 The court previously dismissed the FAC against Medical Director Dr. Nugent (with leave  
28

1 to amend) because the FAC pleaded only a disagreement with Dr. Nugent’s medical decision to  
2 prescribe Humira instead of Enbrel. (ECF No. 48 at 6.) With the aid of further surrounding  
3 allegations in the SAC, the court now better understands plaintiff’s claim against Dr. Nugent, but  
4 the SAC still does not adequately plead that Dr. Nugent was deliberately indifferent in prescribing  
5 Humira instead of Enbrel.

6 With plaintiff’s added allegations regarding the standard packaging and dosing of Enbrel,  
7 it appears that Dr. Nugent misinterpreted plaintiff’s medical file when arriving at his decision to  
8 prescribe Humira instead of Enbrel. Taking plaintiff’s allegations as true, Dr. Nugent seems to  
9 have read the May 24, 2018 nurse’s entry stating that plaintiff had a “current RX Enbrel  
10 50 mg/ml Pen 3.92mls sub Q, weekly” (ECF No. 49 at 15) and assumed that plaintiff had told the  
11 nurse he was taking the entire 3.92 milliliters every week. A review of the April 2018 Kaiser  
12 prescription and Enbrel specifications plaintiff says he provided the medical staff, or of the  
13 publicly available packaging information that Enbrel comes in packs of four syringes each of  
14 which contains a 0.98 mL dose of Enbrel, would have explained the 3.92 milliliters volume (4 x  
15 0.98) that Dr. Nugent seemingly found implausible when deciding what prescription to order.

16 But alleging that Dr. Nugent neglected to consider that information is not enough to state  
17 a claim of deliberate indifference under the Fourteenth Amendment. Gordon, 888 F.3d at 1125  
18 (requiring plaintiffs to “prove more than negligence”). Plaintiff must still allege facts  
19 demonstrating that an official in Dr. Nugent’s circumstances “would have appreciated the high  
20 degree of risk involved” in deciding to prescribe Humira instead of Enbrel. Gordon, 888 F.3d  
21 at 1125. The SAC contains no allegation from which the court can plausibly infer that a doctor in  
22 Dr. Nugent’s position could know that non-Enbrel medications had failed to control plaintiff’s  
23 psoriasis in the past. Plaintiff emphasizes that Dr. Nugent never personally examined or  
24 consulted with him, and none of the medical records attached to the SAC would suggest to a  
25 reasonable reviewer that Humira was known to be ineffective for plaintiff. So it is difficult to see  
26 how a doctor in Dr. Nugent’s reviewing capacity could have appreciated a significant risk in  
27 prescribing Humira as an alternative psoriasis medication. Plaintiff tries to frame the July 2020  
28 doctor notes and grievance reply as admissions that medical staff were aware that Humira would

1 be ineffective. (ECF No. 49 at 8.) But the records themselves make clear that their authors were  
2 simply describing plaintiff’s own contemporaneous assessment of the situation.

3 Simply put, the SAC does not include facts from which the court can infer that it was  
4 “medically unacceptable under the circumstances” to have prescribed Humira instead of Enbrel,  
5 see Toguchi, 391 F.3d at 1058, even assuming that Dr. Nugent’s stated reason for doing so was  
6 faulty. Plaintiff attempts to bridge this gap by alleging that Dr. Nugent prescribed Humira to him,  
7 at age 77, despite Humira generally carrying greater risks for patients over 65 years old. (ECF  
8 No. 49 at 7.) That allegation alone, while perhaps a basis for a negligence or malpractice claim,  
9 is not enough to demonstrate that Dr. Nugent’s choice to prescribe Humira was objectively  
10 unreasonable.

11 It remains the case both pre- and post- Gordon that deciding to prescribe a different  
12 medication than another doctor—or to prescribe a medication other than plaintiff’s preferred  
13 medication—alone, does not support a § 1983 claim. Carlson v. Ada Cty. Jail Med., No. 1:20-  
14 CV-00431-BLW, 2020 WL 6487191, at \*3 (D. Idaho Nov. 4, 2020). And the fact that a patient  
15 has received a certain prescription before going to jail does not mean that a jail doctor necessarily  
16 must make that same prescription available to plaintiff while in custody. See Flentoil, 2020 WL  
17 571025, at \*9. The SAC lacks sufficient allegations to demonstrate that it would have been  
18 “obvious” to a reasonable doctor in Dr. Nugent’s position that there was a high degree of risk that  
19 plaintiff’s psoriasis would flare up unabated if the Enbrel prescription was not restarted. Gordon,  
20 888 F.3d at 1125. And plaintiff’s insistence that Dr. Nugent fabricated and backdated the  
21 May 27, 2018 entry brings him no closer to stating a claim that satisfies the Gordon test.  
22 Accordingly, the claim against Dr. Nugent should be dismissed.

23 **B. Leave to Amend**

24 If the court finds that a complaint or claim should be dismissed for failure to state a claim,  
25 the court has discretion to dismiss with or without leave to amend. Leave to amend should be  
26 granted if it appears possible that the defects in the complaint could be corrected, especially if a  
27 plaintiff is pro se. Lopez v. Smith, 203 F.3d 1122, 1130-31 (9th Cir. 2000) (en banc); Cato v.  
28 United States, 70 F.3d 1103, 1106 (9th Cir. 1995) (“A pro se litigant must be given leave to

1 amend his or her complaint, and some notice of its deficiencies, unless it is absolutely clear that  
2 the deficiencies of the complaint could not be cured by amendment.” (citing Noll v. Carlson, 809  
3 F.2d 1446, 1448 (9th Cir. 1987))). However, if, after careful consideration, it is clear that a claim  
4 cannot be cured by amendment, the court may dismiss without leave to amend. Cato, 70 F.3d at  
5 1105-06.

6 Plaintiff was advised of the deficiencies in his claims against Drs. Drennan, Sahba,  
7 Padilla, and Nugent in the court’s prior order dismissing the first amended complaint and was  
8 provided an opportunity to amend. (ECF No. 48.) The allegations added to plaintiff’s claims  
9 against these doctors still fail to state a claim for relief, for the reasons discussed above. And the  
10 allegations against Dr. Padilla are substantially similar to those the court previously dismissed as  
11 insufficient. Although this is the first time plaintiff has named pharmacist Carter as a defendant,  
12 the failure to include him as a defendant in the first two complaints, combined with the minimal  
13 allegations present in the instant SAC, convince the court that plaintiff is unable to allege in good  
14 faith that Mr. Carter had any control over the complained-of medical treatment. The court  
15 therefore concludes that further leave to amend as to each of these defendants would be futile.  
16 Accordingly, the court recommends dismissing the claims against them with prejudice. See  
17 Hartmann v. California Dep’t of Corr. & Rehab., 707 F.3d 1114, 1130 (9th Cir. 2013) (“A district  
18 court may deny leave to amend when amendment would be futile.”)

## 19 **CONCLUSION**

20 For the reasons set forth above, IT IS HEREBY RECOMMENDED that defendants’  
21 motion to dismiss (ECF No. 52) be DENIED IN PART and GRANTED IN PART as follows:


- 22 1. The motion to dismiss be DENIED as to plaintiff’s Fourteenth Amendment claim against  
23 Dr. Janet Abshire arising from her alleged failure to treat plaintiff’s psoriasis symptoms;  
24 and
- 25 2. The motion to dismiss be GRANTED as to all other claims and defendants, which should  
26 be dismissed from the action with prejudice.

27 These findings and recommendations are submitted to the United States District Judge  
28 assigned to the case, pursuant to the provisions of 28 U.S.C. § 636(b)(1). Within fourteen (14) days



1 after being served with these findings and recommendations, any party may file written objections  
2 with the court and serve a copy on all parties. Such a document should be captioned “Objections  
3 to Magistrate Judge’s Findings and Recommendations.” Any reply to the objections shall be served  
4 on all parties and filed with the court within fourteen (14) days after service of the objections. The  
5 parties are advised that failure to file objections within the specified time may waive the right to  
6 appeal the District Court’s order. Turner v. Duncan, 158 F.3d 449, 455 (9th Cir. 1998); Martinez  
7 v. Ylst, 951 F.2d 1153, 1156-57 (9th Cir. 1991).

8 Dated: December 29, 2020



---

CAROLYN K. DELANEY  
UNITED STATES MAGISTRATE JUDGE

11  
12  
13 19.ervi.1883  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28